Background
Limited information is available on the postnatal immune alterations that may result from developmental (i.e., gestational) exposure of humans and other species to environmental immunotoxicants. However, studies in laboratory rodents suggest that perinatal treatment of animals with a variety of immunotoxic compounds may have more dramatic and persistent effects on subsequent immune function than does exposure during adult life [see review by Holladay and Luster (1) ]. For example, studies show that prenatal exposure of mice to the organochlorine insecticide chlordane results in significant depression of cell-mediated immune responses in offspring that persist for at least 100 days after birth (2, 3) . Alterations in the formation of bone marrow colonies in these mice have been observed to persist up to 200 days of age (4) . This latter effect in particular has not been observed in adult mice after similar dosing with chlordane. Similar to chlordane, the offspring of pregnant mice treated with the polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene (B[a]P), showed long-term (e.g., still present at 18 months of age) depression of antibody, graft-versus-host, and mixed lymphocyte responses (5) . Similar changes in mice after gestational exposure to additional immunotoxic compounds have been associated with reduced ability of the animals to withstand immunologic challenge (e.g., syngeneic tumor cells or bacterial, viral, or parasitic agents) later in life (6) (7) (8) . Together, these reports suggest that in utero immunotoxicant exposure may alter development of immunity, and that such exposure during development may lead to severe and sustained postnatal immunosuppression.
Currently available reports suggest that immune changes, such as those described above, may occur in rodents after exposure to a variety of diverse environmental immunotoxicants, including numerous pesticides, fungicides, heavy metals, carcinogenic PAHs, and polycyclic halogenated hydrocarbons (PHAH) (the most notable and studied member of the latter group being 2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDD]) (1, 9, 10) . The sensitivity of the developing immune system to estrogenic compounds (7, 8, 11) has raised additional questions regarding potential developmental immunotoxicity after gestational exposure to environmental pollutants that are referred to as endocrine disrupters [e.g., 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane (DDT), kepone]. Mycotoxins, such as the trichothecene fungal metabolite T2 toxin, may also warrant concern as developmental immunotoxicants (12, 13 (14) .
However, before these assays are adapted as part of routine developmental toxicity studies, it will be necessary to determine their sensitivity, reproducibility, and predictive value. (17) . Additional studies showed that total numbers of fetal thymic cells decrease in mice after maternal dosing with a broad range of chemically diverse immunotoxic compounds, under a variety of dosing regimens ( Table 1) .
Indicators of Developmental Immunotoxicity
Certain of these compounds (e.g., TCDD and diethylstilbesterol [DES]) produce fetal thymic atrophy after exposure to extremely low levels, supporting the consideration of this parameter as a biomarker of environmental immunotoxicant exposure.
The primary hematopoietic compartment of the fetus is the liver and functions similar to adult bone marrow (23) . Qualitative and quantitative effects of developmental exposure to immunotoxic compounds on fetal liver cellularity have also been examined. Fetal liver hematopoiesis is first detectable in mice by day 10 of gestation and in humans by the sixth week of gestation (24, 25) . This compartment, containing multiple lineages of rapidly proliferating immune cell types, soon thereafter replaces the yolk sac as the primary center of fetal hematopoiesis, a change that persists for the remainder of gestation (23) . Treatment of adult animals with a number of immunotoxic agents, including T2 toxin (26), ethylene glycol monomethyl ether (EGME) (27) , and B[a]P (28) significantly reduces cell counts in the bone marrow. However, recent results indicate that exposure of pregnant animals to immunotoxicants that produce fetal thymic atrophy may or may not result in decreased total hematopoietic cell number in the fetal liver. For instance, dosing of mice with EGME from gd 10-17 reduced cellularity of the gd 18 fetal thymus without altering total cell counts in the fetal liver (22) . Similarly, mice exposed to DES from gd [10] [11] [12] [13] [14] [15] [16] displayed severe reduction of fetal thymic cell counts without altering fetal liver cellularity (11) . Treatment of mice with 1.5 mg/kg T2 mycotoxin from gd 14-17 also reduced thymic cellularity, to 32.5% of the control level, without altering fetal liver cellularity (12) . In contrast, B[a]P reduced both fetal (11) . However, TdT+ cells were reduced, again suggesting possible prothymocyte targeting.
Experiments in which irradiated hosts were reconstituted with stem cells from vehicle or DES-exposed animals demonstrated reduced capacity of the chemicalexposed stem cells to reconstitute the host thymus, indicating that thymic atrophy after exposure to DES may result, at least in part, from a fetal liver lesion at the level of the T-cell progenitor. These data again suggest the use of fetal liver TdT as a sensitive marker of exposure to DES, and possibly other endocrine disrupters. EGME and T2 mycotoxin represent additional immunotoxic agents that alter the expression of immune cell antigens in fetal liver in the presence of unaltered total organ cellularity. Additional reports indicate developmental exposure to B[a]P and DMBA alters fetal liver antigen expression, in the presence of reduced fetal liver cellularity. A summary of fetal liver antigens for which data have been collected after gestational immunotoxicant exposure is presented in In addition to altering surface antigen expression in fetal liver, developmental immunotoxicants have been found to alter surface antigens expressed on fetal thymocytes. Ontogenic development in the fetal thymus originates when prothymocytes of fetal liver origin seed the murine thymic rudiment on gd 10-11. Thymocytes then differentiate and mature in a process that can be followed by CD4 and CD8 cellsurface antigen expression. Initially, thymocytes are double negative (DN) with respect to the CD4 and CD8 antigens. Subsequently, they develop sequentially through immature CD8+ single positive (SP) and CD4+8+ double positive (DP) stages in the thymic cortex, to mature CD4+ SP or CD8+ SP thymocytes in the thymic medulla by gd 18-19 (33,34) . Changes in the normal pattern of thymocyte development have been observed after gestational exposure to a variety of environmental immunotoxicants. For example, mice exposed prenatally to TCDD display altered CD4 and CD8 antigen expression at gd 18 (Table 3) . In particular, TCDD-treated mice displayed reduced percentages of DP thymocytes (the most mature major population present at gd 18) and increased percentages of DN and CD8+ SP thymocytes (the most immature phenotypes present at gd 18), consistent with inhibition of thymocyte maturation. Interestingly, a similar (12, 13) Abbreviations: ND, not determined; +, the compound altered expression of the particular marker; -, the compound did not alter expression of the marker. pattern of altered thymocyte differentiation, including reduced percentages of DP thymocytes and increased percentages of DN thymocytes, has been reported after gestational exposure to a diverse variety of immunotoxic compounds (summarized in Table 4 ).
Although specific mechanisms responsible for such altered thymocyte differentiation after exposure to these compounds have not been elucidated, apoptosis of DP cells may be involved (10) (11) (12) 15, 18, 22) .
In summary, depression of fetal thymic cell counts appears to be a common event after gestational exposure to immunotoxic agents that produce this response in adult animals. The relation of fetal thymic atrophy to postnatal immunosuppression is not known. In contrast, total hematopoietic cell counts in the fetal liver may represent a poor indicator of immunotoxicant exposure. Regardless of whether an immunotoxic compound altered fetal liver cellularity, however, immune cell markers in fetal liver were found to be altered following immunotoxicant treatment in all cases where such data were available. These reports indicate that fetal liver cells may represent highly sensitive targets of immunotoxic chemicals, and, as such, may represent a sensitive indicator of exposure. Similar to fetal liver, altered fetal thymocyte marker expression appears to be a sensitive indicator of gestational immunotoxicant exposure. The findings in fetal liver and thymus agree well with the recent observation in adult rodents that altered immune cell marker expression is a good indicator for immunotoxic agents (14) .
